Skip to main content Skip to main navigation menu Skip to site footer
Confinia Cephalalgica

eISSN 3035-0670 | Official journal of the Italian Society for the Study of Headaches (SISC)

  • About the Journal
  • Publication Ethics
  • Editorial Board
  • Current
  • Archives
  • Copyright
  • Register
  • Login
  • Search
  • Contacts
  • News

Editor-in-Chief: Pierangelo Geppetti, Italy

0.7
CiteScore 2025
0.7
CiteScore 2025
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • PO-45 | Botulinum toxin in clinical practice: a turning point for chronic migraine and MOH Chiara Zilli, Davide Chiffi, Giada Giuliani, Francesca Traccitto, Mariangela Fratino, Marta Altieri | Department of Human Neuroscience, Sapienza University of Rome, Rome, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15867
    189
  • PO-51 | Rimegepant combined with valproic acid and botulinum toxin in refractory hemiplegic migraine: a case report Gianni Difonzo, Cinzia Tamborino, Adriana Fallacara, Damiano Paolicelli, Maria Pia Prudenzano | Headache Center, “L. Amaducci” Neurological Clinic, Policlinico General Hospital, Bari, Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15874
    644
  • Effects of botulinum toxin type A in a migraine-specific animal model

    Chiara Demartini, Rosaria Greco, Sara Facchetti, Miriam Francavilla, Anna Maria Zanaboni, Daniele Martinelli, Cristina Tassorelli
    21-05-2025
    https://doi.org/10.4081/cc.2025.15779
    1425
    PDF: 357
  • PO-88 | Can tamoxifen and metformin nullify efficacy of CGRP-mAbs migraine prophylaxis? Patrizia Rossi,1,2 Valentina Cima,2 Alessandro Burlina2 | 1Headache Center, 2Neurology Department, San Bassiano Hospital, Bassano del Grappa (VI), Italy

    Società Italiana per lo Studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15912
    650
  • Back to the future: a case series on revisiting onabotulinumtoxinA for chronic migraine management after anti-CGRP therapies failure

    Davide Mascarella, Benedetto Carandente, Valentina Favoni, Elisa Maria Bruno, Pietro Cortelli, Giulia Pierangeli, Sabina Cevoli
    03-12-2024
    https://doi.org/10.4081/cc.2024.15767
    924
    PDF: 353
  • PO-62 | Preventive migraine treatment in patients under 25: a 24-month observational study on adherence, therapeutic switching, and prescription determinant factors Marilena Marcosano,1 Nicoletta Brunelli,1 Luisa Fofi,1 Laura Papetti,2 Fabiana Ursitti,2 Massimiliano Valeriani,2 Fabrizio Vernieri,1 Claudia Altamura1 | 1Headache and Neurosonology Unit, Fondazione Policlinico Campus Biomedico di Rome, Rome, Italy; 2Developmental Neurology, Bambino Gesù Children Hospital, IRCCS, Rome, Italy

    Società Italiana per lo studio delle Cefalee (SISC)
    06-11-2025
    https://doi.org/10.4081/cc.2025.15885
    174
1 - 6 of 6 items

authors

FOR AUTHORS
  • SUBMIT YOUR PAPER
  • Guide for Authors
  • Benefits for Authors
  • How to write a scientific paper
  • How to write a Review article

reviewers

FOR REVIEWERS
  • Benefits for Reviewers
  • How to review

Categories

    • Contents

indexing

INDEXING
  • Scopus
  • OpenAlex
  • Analytics

Keywords

Confinia Cephalalgica

is an Open Access, peer-reviewed journal published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS. eISSN 3035-0670 (Website continuously updated).

pISSN: 1122-0279
eISSN: 3035-0670

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission
  • Guidelines For Authors

Our App Is Free For Anyone!

Themes by Openjournaltheme.com

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.